PRESENTATION

Q1 2024 — Presentation

Q1 2024PDF · 33 pages2.8 MB
Merck
Q1 2024 Earnings
April 25, 2024

-- 1 of 33 --

Agenda
2
Strategy and
Business Update
Rob Davis
Chairman and Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 33 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and
are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary
regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward
health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including
obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the
exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report
on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).

-- 3 of 33 --

Strategy and
Business Update
Rob Davis
Chairman and Chief Executive Officer

-- 4 of 33 --

Delivered on our key strategic priorities in Q1 2024
Advanced the pipeline to meet
patient unmet need
Achieved strong commercial and
financial performance
Executed on strategic business
development to augment pipeline
Created long-term value for patients
and shareholders
5

-- 5 of 33 --

20,000
30,000
40,000
50,000
60,000
70,000
2022 	2023 	2024
Strong Q1 sales1 and earnings growth
6
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude expenses for upfront and milestone payments related to certain collaborations and licensing agreements, or
charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. First quarter of 2024 and 2023 include $0.26 and $0.52 per share of such
charges, respectively. Full year non-GAAP outlook for 2024 and full year reported results for 2023 and 2022 include $0.26, $6.21 and $0.22 per share of such charges, respectively. 3. GAAP EPS $1.87.
$15.8B
+9%
+12% ex-Exchange
Q1 Worldwide Sales
Q1 Non-GAAP EPS3
$5.37
Full Year Sales
Full Year Non-GAAP EPS2
$59.3B
+22%
$60.1B
+1%
2022 	2023 	2024
$1.51
$7.48
GUIDANCE RANGE
$63.1B - $64.3B
+5% - +7%
GUIDANCE RANGE
$8.53 - $8.65
$2.07
+48%
Includes one-time charge of $0.26
related to the Harpoon acquisition

-- 6 of 33 --

Maximizing potential impact for patients with cutting-edge science
Vaccines
HPV &
Pneumococcal
Seeking to protect broad
populations globally
Oncology
Diverse Portfolio &
Pipeline
Expanding our impact to
more patients with potential
to improve outcomes
Infectious Disease
HIV
Progressing our clinical
programs focused on the
treatment and prevention
of HIV
7

-- 7 of 33 --

Positioned to deliver the next wave of important innovations
Creating a sustainable
innovation engine that, with
continued clinical success, will
lead to a more diversified
portfolio of growth drivers over
the next decade and beyond
“
”
8

-- 8 of 33 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 9 of 33 --

Strong Q1 worldwide sales growth
10
Merck
WORLDWIDE SALES1,2
$15.8B+9% growth
+12% ex-exchange3
$14.0B
+10% growth
+13% ex-exchange3
Human Health
$1.5B
+1% growth
+4% ex-exchange3
Animal Health
1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue.
3. Updated May 6, 2024: ~2% of the negative impact of foreign exchange for Worldwide Sales and Human Health, and ~3% of the negative impact of foreign exchange for Animal Health, was due to
devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

-- 10 of 33 --

Oncology: KEYTRUDA continues to drive excellent growth
11	Growth rates exclude the impact of foreign exchange.
1. ~4% of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.
• KEYTRUDA sales of $6.9B increased 24% 1
year-over-year, driven by uptake in earlier
stage cancers and continued strong demand
from metastatic indications
– In the U.S., increase largely attributable to
indications in earlier stage NSCLC following
launches of KN-671 and KN-091, as well as strong
uptake following launch of KN-A39 in advanced
urothelial cancer
– Ex-U.S. growth reflects continued uptake in
earlier stage cancers, including high-risk early-
stage TNBC and adjuvant RCC, as well as demand
from metastatic indications
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
1Q22 	1Q23 	1Q24
$4.8B
+27%
$5.8B
+24%
$6.9B
+24%

-- 11 of 33 --

Oncology: Strong performance across broad portfolio
• Lynparza 1 sales grew 7%, driven primarily by
higher demand in certain international
markets
• Lenvima 2 sales grew 10%, driven primarily
by higher demand in the U.S.
• WELIREG sales more than doubled, driven
by the approval of LITESPARK-005 for
certain patients with previously treated
advanced RCC, as well as increased uptake
in VHL disease-associated tumors
$181M
+15%
$151M
+57%
12	Growth rates exclude the impact of foreign exchange.
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
1Q22 	1Q23 	1Q24
$275M
+8%
$266M
+20%
$292M
+7%
1Q22 	1Q23 	1Q24
$232M
+5%
$227M
+77%
$255M
+10%
1Q22 	1Q23 	1Q24
$42M
+128%
$18M
$85M
+102%

-- 12 of 33 --

Vaccines: Robust growth driven by GARDASIL
13
• GARDASIL sales of $2.2B increased 17%
year-over-year driven by global demand
– Sales benefited from timing of shipments in
China and CDC purchasing patterns in the
U.S.
• VAXNEUVANCE grew to $219M, driven
by continued uptake of pediatric
indication in the U.S. and ongoing
launches in Europe
– Sales benefited from CDC purchasing
patterns in the U.S.
$1.2B
+78%
$656M
-24%
$1.7B
+40%$1.5B
+6%
$1.5B
+50%
$1.9B
+27%
Growth rates exclude the impact of foreign exchange.
1Q22 	1Q23 	1Q24
$1.5B
+60%
$2.0B
+43%
$2.2B
+17%

-- 13 of 33 --

Animal Health: Growth across livestock and companion animal
14
• Animal Health sales increased 4% 1 to $1.5B
– Livestock sales growth was driven by price
actions, as well as demand for swine and poultry
products, partially offset by lower demand for
ruminants products
– Companion Animal growth reflects price actions
1Q22 	1Q23 	1Q24
$1.5B
+9%
$1.5B
+5%
$1.5B
+4%
Growth rates exclude the impact of foreign exchange.
1. Updated May 6, 2024: ~3% of the negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with
practice in that market.

-- 14 of 33 --

Q1 2024 non-GAAP financial results summary1
Q1 2024 	Q1 2023 	Change Change
Ex-FX
Sales 	$15.8 	$14.5 	+9% 	+12%
Non-GAAP Gross Margin 	81.2% 	76.9% 	+4.3pts 	+3.8pts
Non-GAAP Operating
Expenses $6.4 	$6.7 	-4% 	-3%
Non-GAAP Tax Rate 	16.1% 	20.4% 	-4.3pts 	N/A
Non-GAAP EPS2,3 $2.07 	$1.40 	+48% 	+54%
$ in billions, except EPS amounts
15
1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of
underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management
uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the
company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income
metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-
GAAP adjustments, see Table 2a attached to the earnings release. 2. Q1 2024 includes $656 million charge, or $0.26 negative EPS impact, for the acquisition of Harpoon. Q1 2023
includes charges of $1.4 billion, or $0.52 negative EPS impact, for the acquisition of Imago and collaboration agreement with Kelun-Biotech. 3. Q1 2024 GAAP EPS of $1.87.

-- 15 of 33 --

Updated 2024 financial outlook
1. Guidance does not assume any additional significant potential business development transactions.
2. One royalty on KEYTRUDA stepped down from 6.5% to 2.5% on 1/1/2024; One royalty on GARDASIL of 7% expired on 1/1/2024.
16
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue 	$62.7B to $64.2B 	$63.1B to $64.3B • 	Assumes ~3% FX headwind (previously ~2%)
• 	Implies growth of 5% to 7% (previously 4% to 7%)
Non-GAAP
Gross Margin Rate ~80.5% 	~81.0% • 	Includes the benefit from reduced royalties paid on
KEYTRUDA and GARDASIL2
Non-GAAP
Operating Expenses1 	$25.1B to $26.1B 	$25.2B to $26.1B • 	Includes $656M one-time charge related to the
acquisition of Harpoon Therapeutics
Other (Income) / Expense 	~$200M of expense 	~$250M of expense
Tax Rate 	~14.5% to 15.5% 	~14.5% to 15.5%
Shares Outstanding 	~2.54B 	~2.55B 	• 	Assumes modest share repurchase
Non-GAAP EPS 	$8.44 to $8.59 	$8.53 to $8.65
• 	Includes one-time ~$0.26 charge related to Harpoon
Therapeutics
• 	Assumes an incremental $0.05 FX headwind
• 	Assumes full year ~$0.30 FX headwind

-- 16 of 33 --

Key modeling considerations
KEYTRUDA
GARDASIL
• 	Increased sales guidance reflects continued growth from
additional indications and patient demand
17
• 	Expect more evenly distributed quarterly shipments to
China this year, which will adversely impact Q2 2024
ex-U.S. growth
LAGEVRIO
• 	Sales in Q1 2024 were driven by COVID-19 incidence in
Asia-Pacific markets, and continue to anticipate lower
sales than 2023

-- 17 of 33 --

WINREVAIR: Excited to bring a novel treatment option
to adult patients with PAH
18
• Confident in successful launch of WINREVAIR,
consistent with prior expectations
• Encouraged by high interest from patient groups
and a range of relevant prescribers
• Several payers have already established coverage
policies, while others are in the process of
developing their policies
• Intend to provide appropriate insights to track
progress, including prescription data and revenue

-- 18 of 33 --

19
Continue to invest in the
pipeline and business while
augmenting the pipeline
with value-enhancing
business development
$2.8
$0.9
$2.0
$1.1
$0.1
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
Q1 Spend ($ in billions)
Remain committed to balanced capital allocation strategy
Capital allocation order of priority
1
1. Reflects R&D excluding Business Development

-- 19 of 33 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 20 of 33 --

WINREVAIR (sotatercept-csrk)
• Received FDA approval for WINREVAIR for
treatment of adults with PAH
• Currently under review by EMA with
decision expected in 2H 2024
• Phase 3 ZENITH and HYPERION studies
ongoing, as well as Phase 2 CADENCE study
21
Expanding the treatment landscape for
patients with Pulmonary Arterial Hypertension

-- 21 of 33 --

Recent Data at CROI1
22
Progress across our HIV clinical program
• In collaboration with Gilead, presented
positive safety and efficacy findings from
Phase 2 study evaluating a once-weekly oral
combination of islatravir and lenacapavir for
treatment of adults living with HIV
• Presented safety and tolerability data for
MK-8527 from two Phase 1 trials evaluating
ascending single dose and multiple doses for
prophylaxis of adults 18 to 55 years old not
infected with HIV
1. Conference on Retroviruses and Opportunistic Infections

-- 22 of 33 --

Important updates across our vaccines programs
23
V116 	HPV Vaccines
• 	Presented positive data from multiple Phase 3
trials at ISPPD1 in March
• 	Potential to be first approved pneumococcal
conjugate vaccine specifically designed to
address the majority of serotypes that cause
invasive pneumococcal disease for individuals
65+2
• 	PDUFA set for June 17th, followed by ACIP
meeting
• Announced new clinical program to identify a
novel multi-valent HPV vaccine candidate
• Plan to initiate clinical trials evaluating short and
long-term efficacy of single-dose GARDASIL 9
versus three-dose regimen
1. International Society of Pneumonia & Pneumococcal Diseases 2. According to CDC data from 2018-2021

-- 23 of 33 --

Diversifying our oncology program and executing on our strategy
Precision Molecular
Targeting
Tissue Targeting	Immuno-oncology
24
Boost anti-tumor immune
responses
Impact pathways that can drive
cancer growth
Increase cancer cell sensitivity
with ADCs and immune-
engagers

-- 24 of 33 --

Committed to harnessing the power of immuno-oncology
25
Immuno-oncology
• 	KEYNOTE-A18: Met primary endpoint of OS for treatment of newly diagnosed patients with high-risk
locally advanced cervical cancer
• 	KEYNOTE-868: FDA granted priority review for 1L treatment of patients with primary advanced or
recurrent endometrial carcinoma (PDUFA June 21 st)
• 	KEYNOTE-671: European Commission approved KEYTRUDA perioperative treatment regimen for
certain adult patients with resectable NSCLC at high risk of recurrence

-- 25 of 33 --

26
Substantial progress across precision and tissue targeting
Precision Molecular Targeting 	Tissue Targeting
• Initiated Phase 3 trial for MK-1084, an
investigational KRAS G12C inhibitor, in
combination with KEYTRUDA for treatment of
certain patients with metastatic NSCLC
• Initiated Phase 2 / 3 REJOICE-Ovarian01 trial
evaluating MK-59091 for treatment of patients with
platinum-resistant ovarian cancer
• Poised to initiate Phase 3 trial evaluating MK-24001
for treatment of certain patients with SCLC
• Completed acquisition of Harpoon Therapeutics,
with lead candidate MK-6070, a T-cell engager
targeting (DLL3) being evaluated in certain patients
with SCLC and neuroendocrine tumors
1. In collaboration with Daiichi Sankyo

-- 26 of 33 --

Key upcoming dates
27
Save the Date:
ASCO Investor Event in Chicago
Upcoming U.S. Regulatory Action Dates:
June 17th
V116 for prevention of invasive pneumococcal
disease and pneumococcal pneumonia in adults
June 21st
KEYTRUDA for primary advanced or recurrent
endometrial carcinoma (KEYNOTE-868)
June 26th
MK-10221 for advanced EGFRm NSCLC
(HERTHENA-Lung01)
1. In collaboration with Daiichi Sankyo.

-- 27 of 33 --

Q&A
Rob Davis
Chairman & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 28 of 33 --

Appendix
29

-- 29 of 33 --

Q1 2024 GAAP financial results summary
30
Q1 2024 	Q1 2023 	Change 	Change Ex-FX
Sales 	$15.8 	$14.5 	+9% 	+12%
Operating Expenses 	$6.5 	$6.8 	-4% 	-3%
Tax Rate 	15.9% 	22.6% 	-6.7pts 	N/A
GAAP EPS 	$1.87 	$1.11 	+68% 	+76%
$ in billions, EPS amounts

-- 30 of 33 --

$11.0
$3.7
$7.5
$17.7
$1.3
$0
$3
$6
$9
$12
$15
$18
$21
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$ 18B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Billions
$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$2.76
$2.92
$3.08
$1.40
$1.70
$2.00
$2.30
$2.60
$2.90
$3.20
2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023 	2024
Dollars per share	
+2% 	+2% 	+2% 	+2%
+11%
+15%
+7%
Over the past 12 months
Capital investments
2023 to 2027
Commitment to the dividend
31
Well-positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
+6%
Order of priority
+6%
1. 	Reflects R&D excluding Business Development
2. 	Includes BD payments reflected in operating cash flow
2
1
E
+5%
E

-- 31 of 33 --

Driving value for patients and shareholders by progressing our pipeline
32
Key regulatory milestones since
the last earnings call:
Key data & clinical advancements since the last earnings call:
• In the U.S.:
o FDA accepted for priority review the sBLA for
KEYTRUDA in combination with chemotherapy,
followed by KEYTRUDA as a single agent for the
treatment of patients with primary advanced or
recurrent endometrial carcinoma based on
NRG-GY018 (KEYNOTE-868)
o FDA approved WINREVAIR for the treatment of
adults with pulmonary arterial hypertension
based on STELLAR
• In the EU:
o EC approved KEYTRUDA as part of a treatment
regimen in the perioperative setting for the
treatment of certain patients with resectable
NSCLC at high risk of recurrence based on
KEYNOTE-671
1. FDA approval of KEYTRUDA in combination with CRT for treatment of patients with FIGO 2014 Stage III-IVA cervical cancer 2. In collaboration with Daiichi Sankyo
• 	Presented positive data from multiple Phase 3 studies evaluating V116, an investigational
21-valent pneumococcal conjugate vaccine for adults, at the International Society of
Pneumonia and Pneumococcal Diseases
• 	Presented results from the Phase 2 study evaluating islatravir, an investigational
nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class
capsid inhibitor, in the treatment of patients with HIV at the Conference on Retroviruses
and Opportunistic Infections
• 	Announced Phase 3 KEYNOTE-A181 trial evaluating KEYTRUDA in combination with
chemoradiotherapy met its primary endpoint of overall survival for the treatment of newly
diagnosed patients with high-risk locally advanced cervical cancer
• 	Announced plans to initiate clinical development of a new investigational multi-valent HPV
vaccine and to conduct clinical trials evaluating whether a single-dose regimen of
GARDASIL 9 provides comparable long-term protection to the approved three-dose
regimen at the EUROGIN 2024 HPV Congress
• 	Initiated Phase 3 trial evaluating MK-1084, an investigational oral selective KRAS G12C
inhibitor, for the treatment of certain patients with metastatic NSCLC
• 	Initiated Phase 2/3 REJOICE-Ovarian01 trial evaluating raludotatug deruxtecan (R-DXd)2
for the treatment of patients with platinum-resistant ovarian cancer

-- 32 of 33 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V181
Dengue Virus
Vaccines
Infectious disease
MK-8189 4
Schizophrenia
Neuroscience
Gefapixant (MK-7264)5
Cough (US)
General medicine
As of April 25, 2024
Infectious disease
Oncology 	Oncology
MK-8527
HIV-1 prevention
MK-8591B (islatravir+MK-8507)1
HIV-1 infection
MK-8591D (islatravir+lenacapavir)2,11
HIV-1 infection
MK-1022 (patritumab
deruxtecan)6
NSCLC (EU)
MK-1026 (nemtabrutinib)
Hematological
Malignancies
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-2870 (sacituzumab
tirumotecan)7
Breast
Endometrial
NSCLC
MK-3543
(bomedemstat)
Myeloproliferative
Disorders
KEYTRUDA (MK-3475)
CSCC (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
SCLC
MK-3475A (pembrolizumab
+hyaluronidase)
NSCLC
MK-4280A (favezelimab
+pembrolizumab)
CRC
Hematological Malignancies
MK-5684 (opevesostat)13
Prostate
WELIREG (MK-6482)
RCC (EU)
LYNPARZA (MK-7339)8
NSCLC
SCLC
LENVIMA (MK-7902)9
Esophageal
Gastric
MK-7684A (vibostolimab
+pembrolizumab)
Melanoma
NSCLC
SCLC
V940 10
Melanoma
NSCLC
MK-8591A
(doravirine+islatravir)2
HIV-1 Infection
KEYTRUDA (MK-3475)
Resectable NSCLC (JPN)
1L Urothelial (EU, JPN)
1L HER2- Gastric (JPN)
1L Biliary (JPN)
Endometrial Carcinoma (US, EU, JPN)
Cervical (EU, JPN)
MK-1022 (patritumab deruxtecan)6
NSCLC (US)
WELIREG (MK-6482)
Certain VHL tumors (EU)
Advanced RCC (EU)
MK-2060
Thrombosis
MK-5475
PH-COPD
MK-6024 (efinopegdutide)
NASH
WINREVAIR (MK-7962)
Pulmonary Hypertension due to Left
Heart Disease
Cardiometabolic
MK-4280A
(favezelimab+pembrolizu
mab)
Bladder
cSCC
Endometrial
Esophageal
Melanoma
RCC
MK-5890 (boserolimab)
Neoplasm Malignant
MK-5909 (raludotatug
deruxtecan)6
Ovarian
MK-2870 (sacituzumab
tirumotecan)7
Neoplasm Malignant
KEYTRUDA (MK-3475)
Advanced Solid Tumors
Prostate
KEYTRUDA (MK-3475A)
cSCC
MK-4280
(favezelimab)
NSCLC
LYNPARZA (MK-7339)8
Advanced Solid Tumors
LENVIMA (MK-7902)9
HNSCC
WELIREG (MK-6482)
Endometrial
Esophageal
HCC
Prostate
Rare Cancers
MK-7684A
(vibostolimab
+pembrolizumab)
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Ovarian
Prostate
RCC
V940 10
Bladder
RCC
MK-1022 (patritumab
deruxtecan)6
Gastric
Melanoma
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
CRC
MK-2140 (zilovertamab
vedotin)
Hematological Malignancies
MK-2400 (ifinatamab
deruxtecan)6
CRC
SCLC
Broad and innovative pipeline to address significant unmet medical needs
Vaccines
MK-1654 (clesrovimab)
Respiratory Syncytial
Virus (RSV)
1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials	
3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma 5FDA issued CRL in December 2023	
6 In collaboration with Daiichi Sankyo 7In collaboration with Kelun-Biotech 8 In collaboration with AstraZeneca 9 In collaboration with Eisai	
10In collaboration with Moderna 11In collaboration with Gilead 12Developed under an agreement with Ridgeback Bio 13 In collaboration with Orion
Cardiometabolic
MK-7240 (tulisokibart)
Ulcerative Colitis
Immunology
MK-0616
Hypercholesterolemia
WINREVAIR (MK-7962)
Pulmonary Arterial Hypertension (EU)
Cardiometabolic
LAGEVRIO (MK-4482)3,12
COVID-19 antiviral
Vaccines
V116
Pneumococcal conjugate vaccine, adult (US, EU)
MK-6194
Vitiligo
Immunology

-- 33 of 33 --